<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681847</url>
  </required_header>
  <id_info>
    <org_study_id>Ehab-Walaa.Hypertonic</org_study_id>
    <nct_id>NCT03681847</nct_id>
  </id_info>
  <brief_title>Crystalloids Versus Colloids Versus Hypertonic Saline as a Co-load During Spinal Anesthesia.</brief_title>
  <official_title>Crystalloids Versus Colloids Versus Hypertonic Saline Co-load During Spinal Anesthesia: Which is More Effective</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal anesthesia is commonly accompanied by hypotension due to vasodilation that follows
      sympathetic blockade and decreased systemic vascular resistance. Prevention of hypotension is
      usually achieved through administration of fluids and vasopressors .There is an ongoing
      debate concerning both the proper fluid timing, pre-load against co-load and fluid type
      crystalloids against colloids .This study aims at comparing the effectiveness of co-loading
      of crystalloids versus colloids versus hypertonic saline 3% in preventing hypotension induced
      by spinal anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal anesthesia is commonly accompanied by hypotension due to vasodilation that follows
      sympathetic blockade and decreased systemic vascular resistance. Prevention of hypotension is
      usually achieved through administration of fluids and vasopressors . Fluids are either
      administrated before initiation of spinal anesthesia which is defined as fluid pre-loading or
      at time of initiation of spinal anesthesia which is defined as fluid co-loading .There is an
      ongoing debate concerning both the proper fluid timing, pre-load against co-load and fluid
      type crystalloids against colloids. Fluid preloading with colloids appears to have superior
      effect on that of crystalloids as the later shows a shorter intravascular half-life. While
      both colloid and crystalloid co-loading show comparable results .Although crystalloid
      preloading has been the traditional regimen for long time, it failed to reduce the incidence
      of hypotension. This is because crystalloids rapidly distribute out of the intravascular
      compartment to the interstitial space. Superiority of fluid co-loading might be explained by
      decrease of the extravascular crystalloid redistribution secondary to the simultaneous
      vasodilatation response to sympathetic block.This study aims at comparing the effectiveness
      of co-loading of crystalloids versus colloids versus hypertonic saline 3% in preventing
      hypotension induced by spinal anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypotension</measure>
    <time_frame>3 hours</time_frame>
    <description>The development of hypotension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum sodium level</measure>
    <time_frame>3 hours</time_frame>
    <description>measurement of serum sodium level</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Spinal Anaesthesia</condition>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive normal saline 0.9% 15 ml/kg over 15-20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxyethyl starch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive hypertonic saline 3% (7ml/kg) over 15-20 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>normal saline 0.9% 15 ml/kg over 15-20 minutes.</description>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hydroxyethyl starch</intervention_name>
    <description>hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.</description>
    <arm_group_label>Hydroxyethyl starch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>hypertonic saline 3% (7ml/kg) over 15-20 minutes.</description>
    <arm_group_label>Hypertonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years

          -  ASA II-III

          -  Elective lower abdominal surgeries

        Exclusion Criteria:

          -  Coagulation defects

          -  Abnormal kidney or liver functions

          -  Local infection at site of injection

          -  Uncontrolled hypertension

          -  Bone metastases

          -  Cardiac disease

          -  Elevated serum sodium level &gt; 145 mEq/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehab H Shaker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute- Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesia and Pain medicine.National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/2528143</url>
    <description>Colloid versus Crystallid Co-load with Spinal Anesthesia during Emergent Cesarean Section and Their Effect on Hemodynamic Changes.Lotfy ME; Moustafa AM; Elham M.E, et al. J Am Sci 2014;10(11):158-163]</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Ehab Hanafy Shaker</investigator_full_name>
    <investigator_title>lecturer of anesthesia ,critical care and pain medicine</investigator_title>
  </responsible_party>
  <keyword>hypertonic saline</keyword>
  <keyword>colloids</keyword>
  <keyword>normal saline</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>after finishing and publishing the study we plan to share it.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

